A mouse monoclonal anti-idiotypic (anti-id) immunoglobulin M (IgM) antibody, called MAb2, was raised against a mouse monoclonal anti-cholera toxin (anti-CT) antibody (MAb1). The MAb2 was shown, by competition with CT for MAb1, to bear the internal image of an epitope of CT. MAb2 immunization of rats was performed via the intraperitoneal, intragastric, and intrajejunal routes and compared with immunization of rats with either a control, isotype-and allotype-matched MAb or with CT via the same routes. Both serum IgG and bile IgA anti-CT Ab3's were detected by enzyme-linked immunosorbent assay in anti-id MAb2-immunized rats, although their titers were lower than those in CT-immunized rats. No anti-CT antibodies were detected in sera and bile of rats immunized with the control MAb. When tested for degree of gut protection against a CT challenge, rats immunized with MAb2 by the intrajejunal route showed a rather high degree of protection, which was only slightly lower than that of rats i...
Vibrio cholerae is a gram-negative pathogen which still kills many humans by dramatic diarrhea, mainly in developing countries. The actual cause of the diarrhea is the cholera toxin (CT) actively secreted by the vibrios which have colonized and proliferated in the small gut. There are great similarities in antigenicity, amino acid sequence, and pathogenicity between CT and the various heat-labile toxins secreted by enterotoxigenic Escherichia coli (21, 44) . Vaccination against these enterotoxins, which are responsible for about half of the deaths from diarrhea in the Third World (27) , although a major goal, has not yet been adequately achieved, despite recent promising results with a preparation combining whole cells and the B subunit of CT (CT-B) (2, 4, 5) .
We have used the idiotypic (id)-anti-idiotypic (anti-id) immune network (12) as a new approach to such a vaccine. Several examples of successful anti-id immunizations against various viruses, bacteria, and parasites have already been reported (for reviews, see references 7 and 10), but none has yet been reported against CT. In a preliminary study (23) , we reported that rats, after repeated intraperitoneal (i.p.) injections of a mouse auto-anti-id monoclonal antibody (MAb) , not only acquired serum and bile anti-CT Ab titers but were also significantly protected against a CT challenge in their ligated gut loops.
CT acts at the level of the intestinal epithelium, and it is known that intestinal secretory immunoglobulin A (IgA) anti-CT Ab is most important for protection against an in vivo gut CT challenge (25, 26, 32, 34, 36, 43, 45) . We therefore compared the anti-CT Ab response of rats repeat-* Corresponding author.
edly immunized with a mouse anti-id MAb (MAb2) or with a control non-anti-id MAb, by both enteral and parenteral routes, to the direct anti-CT Ab response of rats after several injections of CT by the same routes. The aim was to investigate the feasibility of anti-id immunization via the enteric route, the usual way to stimulate the common mucosal immune system (30) . Enteric immunizations with CT are well documented, and it was of interest to compare anti-id and CT immunizations via the same routes for resulting Ab titers and protective capacities.
We report the following in this article: (i) the production and characterization of a mouse anti-id MAb (or MAb2), which mimics (internal image or Ab2p) an epitope of CT; (ii) the induction by repeated enteral and parenteral injections of this MAb2 into rats, but not of a non-anti-id control isotypematched MAb, of IgG and IgA anti-CT responses (Ab3) in the sera and bile of the rats, the latter response probably reflecting a local gut response (20, 36) ; (iii) the protection against a CT challenge in gut loops afforded by anti-id MAb2 immunizations but not by control MAb immunizations; (iv) a comparison of serum and biliary anti-CT Ab titers with degree of gut protection among rats similarly immunized with anti-id MAb2, control MAb, or CT; and (v) a characterization of rat serum anti-CT Ab3 in comparison with various monoclonal and polyclonal anti-CT Abs.
MATERIALS AND METHODS
Mouse MAb against CT (MAbl). This id MAbl (4C5 IgGl) was obtained from mice immunized three times intrajejunally (ij.) with 30 ,ug of CT and boosted i.p. with a fourth dose of 50 ,ug of CT as described earlier (22) . Other MAbs 3651 against CT such as 5B5, also described previously (22) , were used as controls for the anti-id specificity of MAb2; all reacted only with CT-B (22) . In some instances, polyclonal affinity-purified anti-CT Abs (35) from mouse origin were also used, as well as normal mouse polyclonal IgG and IgM, purified by Sepharose-protein A (Pharmacia, Uppsala, Sweden) chromatography and gel filtration on Ultrogel AcA22 (Industrie Biologique Francaise, Villeneuve-la-Garenne, France).
Mouse anti-id MAb2. BALB/c mice were immunized three times i.p., 2 weeks apart, with 50 jig of MAbl in 0.1 ml of 0.01 M phosphate-buffered saline, pH 7.4 (PBS), with 0.2% (wt/vol) gelatin (PBSG): the first injection was a mixture with an equal volume of complete Freund adjuvant, and the two others were mixtures with equal volumes of incomplete Freund adjuvant. After a 4-week rest, the mice were boosted intravenously with 100 ,ug of MAbl in PBSG, and the splenocytes, collected 4 days later, were fused with NSO/1 cells (8) and plated in hybridoma growth medium, as described previously (20) . By using a particle-counting immunoassay (described below), three anti-MAbl Ab-secreting clones (two IgM and one IgG) were detected, and one of them, the IgM-secreting 3F10 MAb2 clone, was selected because of its efficient competition with CT for MAbl and its unique reactivity with MAbl (see Results). After subcloning by limiting dilutions, about 2 million cells were injected i.p. into pristane-treated, irradiated (230 rads) BALB/c x NMRI hybrid mice. After 7 days, ascitic fluid was collected, clarified by centrifugation, salted out with ammonium sulfate (adjusted to pH 6.8 with ammonia) at 20% saturation to insolubilize residual fibrinogen, and centrifuged. The supernatant was then precipitated with ammonium sulfate at 50% saturation and centrifuged, and the pelleted Igs were dissolved in and dialyzed against the buffer for gel filtration on an Ultrogel AcA22 column (100 by 2.5 cm). The eluates containing the IgM peak, as detected by particle-counting immunoassay with MAbl-coated latex (Lx) particles, were pooled and concentrated by pressure ultrafiltration (Amicon 8200, Rotterdam, Holland). As a control, non-anti-id, isotype-matched MAb, an irrelevant mouse IgM MAb against Brucella melitensis lipopolysaccharide (LPS) that was obtained as described earlier (20) , was purified from ascites as described for the anti-id MAb2 IgM.
For some experiments, another auto-anti-id [anti-(anti-CT)] MAb, a monomeric IgM (1) secreted by a clone isolated directly from the spleen of CT-immunized mice (23) , was also used.
Immunoassays by Lx particle counting. Lx particles were coated, as described previously (22) ,.1 of GBS containing 10 mg of bovine serum albumin per ml (GBS-BSA), and 25 ,ul of "agglutinator" was incubated for 30 min at 37°C with continuous vortexing. The reaction was stopped by a constant dilution of the mixture with 2.0 ml of GBS. For agglutination inhibition assays, the GBS-BSA was replaced with 25 RI1 of "inhibitor," which was preincubated either with the coated Lx particles or with the agglutinator for 15 to 30 min at 37°C, before the final reaction was performed by reincubating the complete mixture for 15 min at 37°C, followed by the final constant dilution with 2.0 ml of GBS and then the counting of the Lx particles. Agglutination of Lx particles was assessed by particle counting, the diluted mixture being aspirated by a peristaltic pump and passed through the flow cell of an optical counter by using forward light scattering. Only free unagglutinated Lx particles were counted, and they were registered as peak heights (or as percentage of free particles) on a recorder (3, 28) . Thus, the stronger the agglutination, the fewer free particles, and the smaller the recorded peak height, and conversely.
ELISA for rat anti-CT Abs. It was first observed that most rat sera, even before immunization, had unexplained but strong agglutinating properties for Lx particles coated with CT (unpublished results), rendering the particle-counting immunoassay unpracticable for assaying rat anti-CT Abs. Therefore, we developed IgG and IgA anti-CT enzymelinked immunosorbent assays (ELISAs). Microtiter plates (with 96 wells; Greiner, Nurtingen, Germany) were coated with CT at 4.0 p,g/ml in 0.2 M carbonate-bicarbonate buffer (pH 9.5). Residual protein-binding sites were blocked with PBS containing 1% bovine serum albumin (PBS-BSA). Dilutions of samples, starting at 1/20, were performed in PBS-BSA with 0.1% (vol/vol) Tween 20. For each rat, serial double dilutions of serum or bile were incubated for 2 h on CT-coated plates at 37°C. Rat anti-CT Abs were revealed with horseradish peroxidase-coupled (31) affinity-purified polyclonal rabbit IgG Abs specific for rat a or -y chains, prepared in our laboratory, or with a peroxidase-labelled mouse MAb against rat a chains (MARA-2; purchased from H. Bazin, Experimental Immunology Unit, Catholic University of Louvain, Brussels). Standard IgG and IgA anti-CT curves were included in each plate, as well as control curves derived with serum and bile from unimmunized rats. The standard for serum anti-CT IgG was the serum of a rat immunized four times i.p. with 50 ,ug of CT at 2-week intervals. For anti-CT IgA, the standard was pooled bile from rats immunized two times i.j. with 25 ,ug of CT (45) and collected as described previously (18) at day 4 after the last injection. A 1/1,000 dilution of the standard IgG serum was defined as containing 1,000 arbitrary units of anti-CT IgG. A 1/200 dilution of the bile secretory IgA standard was assumed to contain 1,000 arbitrary units of anti-CT intestinal secretory IgA. The anti-CT IgG or IgA ELISA titer of an individual rat serum or bile sample was expressed in arbitrary units, calculated from the optical densities (optical density at 492 nm -optical density at 405 nm) of at least three serial double dilutions of serum and bile, each in duplicate, falling in the sensitive range of the corresponding standard curve. Specificity of this ELISA was first shown by mixing rat serum Ab3 with various amounts of CT before incubation in CT-coated wells, thereby inhibiting Ab binding and subsequent color development.
Immunization of rats with anti-id MAb2, control IgM MAb, or CT. MAb2, control IgM MAb, or CT (generously provided by the Institut Merieux, Marcy-l'Etoile, France), all at a 50-,ug dose in PBSG, were injected into outbred SpragueDawley specific-pathogen-free rats (250 to 300 g; IFFA-CREDO, Brussels) by the i.p. route (in 200 R1 with complete or incomplete Freund adjuvant, four times, 2 weeks apart), by intragastric (i.g.) intubation during a short ether anesthesia (in 1.0 ml containing 3% NaHCO3, four times, 2 weeks apart) by using a small catheter, or by i.j. injection (in 200 I,l, three times, 2 weeks apart), i.e., directly into the upper jejunum after laparotomy under anesthesia. The ij. route was used, despite need for surgery, to ensure total antigen dose delivery into the small gut, in contrast with the i.g. route.
Protection test: CT challenge into ligated jejunal loops (17) . Because all rats in one group could not be operated on within 1 day, rats were taken for testing at 4 or 5 days after the last injection and fasted with free access to water for 24 h before laparotomy under ether anesthesia, and, after bile duct cannulation (18) (usually requiring <30 min but sometimes requiring -120 min in the ij. group) with a narrow polyethylene catheter passed through the lateral skin for extracorporeal bile collection, two 5-cm-long loops in the upper jejunum, chosen because they were free of visible intestinal contents, were ligated with double knots, respecting the integrity of large mesenteric vessels. Purified CT (1 ,ug in 0.5 ml of PBSG) or 0.5 ml of PBSG was injected into these loops with a 30-gauge needle. The abdomen was then closed, and the animal was put in a restraint cage, with bile flowing from the animal via a tube positioned about 10 cm below it. After 4 h, the rats were killed by ether overdose and bled out. The two ligated gut loops with their fluid contents were carefully dissected and weighed. The fluid accumulation (weight/ length ratio [in milligrams per centimeter] of CT-injected loop minus that of PBSG-injected loop) was calculated for each animal. Control CT challenges were always performed in unimmunized rats of the same age. The mean fluid accumulation of PBSG-injected loops was taken arbitrarily to be 100% protection, and the mean fluid accumulation of CT-injected loops in unimmunized control rats was arbitrarily taken to be 0% protection. The percentage of protection for each immunized or control rat was thus calculated as follows: Immunoabsorbents. Normal BALB/c mouse serum was precipitated with ammonium sulfate at 40% saturation. The precipitated Igs were dissolved, dialyzed against 0.1 M carbonate-bicarbonate buffer (pH 8.5), and coupled to CNBr-activated CL-Sepharose 4B (Pharmacia) beads as described by the manufacturer. Slow percolation of rat Ab3 sera through a column made of this immunosorbent (2.5 ml of packed immunosorbent per ml of rat serum) was used to absorb rat anti-mouse Ig Abs. The percolated sera (FT-Ab3) were reconcentrated to a volume 10-fold larger than the original (FT-Ab3 = original rat sera at 1/10); this was required to avoid agglutination of MAb2-Lx by the antimouse Ig activity in rat Ab3 sera. A small (5-ml) CT immunoabsorbent was also prepared, as reported earlier (35) , to purify rat anti-CT Ab. The acid-eluted, neutralized Ab solution (E-Ab3) was concentrated to 10-fold the serum volume (E-Ab3 = original sera at 1/10) and was then used to represent purified anti-CT Ab present in rat Ab3 sera. 
RESULTS
Characterization of anti-id MAb2 (IgM 3F10). To show that MAb2 was a true anti-MAbl anti-id Ab we first demonstrated that only MAbl-Lx was agglutinated by MAb2 and not any other anti-CT MAb-Lx, anti-CT polyclonal Ab-Lx, control anti-LPS MAb-Lx, or polyclonal normal mouse IgG-Lx, all of these other Lx particles showing the same absence of agglutination (Fig. 1A) . Conversely, when MAb2 was coated on Lx particles, the MAb2-Lx was only agglutinated by MAbl (Fig. 1B) wllo:i"-" :i"'-q 6"'-" i MAb2-Lx. This indicates that CT behaves as an inhibitor of the MAb2-Lx agglutination by MAbl (Fig. 2B ) and thus that MAb2 bears an internal image of a CT epitope.
In a similar test, but with a different anti-CT MAb-Lx (5B5-Lx) and a different anti-id MAb (namely, the autoanti-id MAb studied previously [23] ), the addition of CT did not influence the agglutination of the anti-CT MAb-Lx by this other auto-anti-id MAb (Fig. 2C) . These results show that the competition we have obtained with our MAb2 is not due to the steric hindrance caused by the binding of the CT on the paratope (or binding site for CT) of the MAbl. Together, the data from Fig. 1 and 2 Table 1 . In contrast to rats immunized with the control MAb, both CT-immunized and MAb2-immunized rats developed anti-CT ELISA titers which were inhibitable by CT. For all CT-immunized rats, less than 1 p,g of CT per ml was enough to obtain 50% inhibition; for rats immunized with MAb2 i.p., four of eight Ab3 serum samples required -500 ,ug/ml for 50% inhibition, but the four others required only 110, 37, 28, and 20 ,ug/ml.
The results of the protection tests against intestinal CT challenge are also shown in Table 1 , allowing comparisons between serum and bile anti-CT titers on the one hand and fluid accumulation and percent protection on the other, within and between the different groups of rats.
In general, rats immunized with CT had much higher anti-CT Ab titers than rats immunized with MAb2, and rats immunized with the control MAb had no significant anti-CT IgG or IgA. The mean percentages of protection in the three subgroups of CT-immunized rats were roughly correlated with the mean ELISA titers of bile anti-CT IgA. There was, however, no such correlation between serum IgG or bile IgA titers and percent gut protection for the MAb2-immunized animals; for these, the ij. route yielded a higher percentage of protection than the i.p. or i.g. route (i.j. versus i.p. or i.g., P = 0.061 or 0.100, respectively, by unpaired Student's t test). Also, for rats immunized with CT, the i.j. route was more protective than the i.p. or i.g. route (P = 0.002 or 0.255, respectively). The control MAb-immunized rats showed virtually no protection, the percent being lower than that of both the MAb2-immunized (P = 0.105 and 0.001 for the i.p. or i.j. route, respectively) and CT-immunized (P = 0.002 and <0.001 for the i.p. or ij. route, respectively) animals. Finally, the percentage of protection was not significantly different between the MAb2 ij. and the CT ij. subgroups (P = 0.118).
Characterization of rat anti-CT Ab3 response in serum. To further study the rat anti-CT Ab3's by the particle-counting method with MAb2-Lx or MAbl-Lx (CT-Lx could not be used [see Materials and Methods]), we had to eliminate the anti-mouse Ig Abs that were also induced when rats were immunized with mouse MAb2. This was done in two different ways. First, non-anti-id anti-mouse Ig Abs were removed from rat Ab3 sera by absorption on an immunosorbent of normal mouse Igs. This yielded 10-fold-diluted rat serum (i.e., FT-Ab3). In a second approach, rat CT-reactive Abs were directly purified from Ab3 sera by immunoabsorption on and elution from CT-Sepharose. This yielded an eluate (i.e., E-Ab3) containing affinity-purified rat serum anti-CT Ab3, diluted 10-fold with respect to the original serum.
MAb2-Lx was agglutinated by FT-Ab3 (and E-Ab3 [data not shown]) but not by non-MAbl anti-CT MAbs used as agglutinators (Fig. 3A) . This agglutination of MAb2-Lx by FT-Ab3 (and E-Ab3 [data not shown]) could be specifically inhibited by anti-id MAb2 only and not by other anti-CT MAbs (Fig. 3B) , the control MAb, or normal polyclonal mouse IgM, indicating that the rat anti-CT Ab3 response indeed resulted from immunization with the mouse MAb2.
The specificity of anti-CT in FT-Ab3 and E-Ab3 was very similar to that of MAbl, in agreement with the id network. FT-Ab3 (and E-Ab3 [data not shown]) inhibited the agglutination of MAbl-Lx by MAb2, as did MAbl itself, whereas no other non-MAbl anti-CT MAb (nor mouse or rat serum polyclonal anti-CT Abs) inhibited this agglutination (Fig.  4A) . Also, the agglutination of MAbl-Lx by CT was inhibited by FT-Ab3 (and E-Ab3 [data not shown]) as well as by MAbl (Fig. 4B) . These results strongly suggest that this rat serum anti-CT Ab3 response was of the same specificity as that of id MAbl and confirm that the present anti-id MAb2 actually mimicked a CT epitope. DISCUSSION We have demonstrated that anti-id immunization against CT, by using as immunogen a mouse anti-id MAb2 IgM against a mouse anti-CT id MAbl but not an isotypematched control MAb, was obtained in rats both by enteral (i.j. and i.g.) and parenteral (i.p.) routes and induced a relatively high percentage of protection against an intestinal CT challenge in many of the ij. MAb2-immunized rats but not in control MAb-immunized rats. This extends the already long list of pathogenic systems in which anti-id immunization, with (6, 9, 13, 15, 16, 37, 40) or without protection, has been demonstrated. Our study is also the second example in which anti-id immunization and protection were obtained by stimulation of the mucosal immune system, namely, by using i.g. and ij. immunizations. Recently (11) , Abs against Streptococcus mutans and some degree of protection against caries induced by this pathogen were obtained in germfree rats after repeated parenteral (intrasalivary gland) or enteral (i.g.) injections of polyclonal rabbit anti-rat-id affinity-purified Abs; in the case of the i.g. intubations, the anti-id Abs were encapsulated within liposomes to enhance their immunogenicity.
Rats immunized with an irrelevant, non-anti-id monoclonal mouse IgM, used as a negative, normal control for MAb2 immunization, displayed no detectable production of anti-CT Abs in serum and bile by exactly the same assays used for the MAb2-and the CT-immunized rats. Also, except for a single rat in the ij. control MAb-immunized group, there was no protection against the CT challenge.
A potential problem with our data could be the lack of correlation (data not shown) between individual serum or biliary anti-CT Ab3 titers, on the one hand, and the percentage of protection against the gut CT challenge in the same animals on the other hand. Such a correlation, which has been obtained with oral immunizations directly with CT or CT-B mixed with traces of CT (24), would nevertheless seem desirable if anti-id vaccination is to become more generally acceptable. On the other hand, when protection was obtained with other anti-id immunization models, correlations between degree of protection and Ab titers were rather poor (29) or not even mentioned.
Although our highest mean protection with anti-id immunization via the ij. route was 66.13%, i.e., not significantly (P = 0.118) lower than the 86.5% with i.j. CT immunization, it should be emphasized that CT is known as an extremely potent immunogen, even via the oral route. In fact, it would have been better to compare our anti-id immunizations with CT-B immunizations, because pure CT-B, like our anti-id MAb2, does not contain any native CT. It was demonstrated (24) that even repeated oral immunizations with CT-B devoid of any CT did not induce any significant protection, despite the presence of some anti-CT Ab responses. To obtain significant, but weak, gut protection, the CT-B oral immunizations required the presence of at least 5% CT (24) . Hence, the mean degree of intestinal protection observed after our anti-id MAb2 immunizations was indeed remarkable.
Several factors might be cited to explain our lack of correlation between Ab3 ELISA titers and degree of protection. Cannulation of bile, just before preparing and testing the loops, diverted some bile from the challenged loops; the more difficult the bile cannulation, the more bile (and probably anti-CT IgA) was diverted from the loops just before their challenge, which could influence the protection tests in view of the importance of bile IgA for the upper rat gut (21, 36) . Also, the quality of the Ab could influence the protection tests. In this context, for the eight i.p. MAb2-immunized rats, the IgG anti-CT ELISA inhibition tests had a tendency to correlate with the percentage of protection. Indeed, whereas the sera from those four rats with no degree of protection required at least 500 ,ug of CT per ml for 50% optical density inhibition, the sera from rats with protection levels of 3, 59, 82, and 90% required only 37, 110, 27, and 20 ,ug of CT per ml, respectively, without correlation with the serum IgG ELISA titers. This suggests that not only the titer, but also some quality of Ab3, might be important in terms of protection. In addition, we ignore the kinetics of anti-CT Ab3 responses; the delay of 4 to 5 days between the last anti-id injection and the gut challenge might not correspond with individual peak anti-CT Ab3 responses. In the case of oral CT immunization, peak numbers of anti-CT Ab-secreting cells usually occur at 8 days after the last booster (26) . A remote explanation could also be a contribution of IgM anti-CT Ab3, which we have not measured here because, thus far, no significant role of IgM was reported in gut protection against CT challenge. Finally, we cannot rule out, as suggested by others (14) , a participation of some T-cell reaction in the fluid accumulation, such as delayed-type hypersensitivity, in addition to the well-demonstrated inhibitory role of anti-CT antibodies.
Clearly, it would be of major interest to unambiguously correlate local intestinal IgA anti-CT Ab content (rather than just in bile) and/or numbers of IgA Ab-secreting cells in the wall of the challenged loops with the degree of protection. Such studies are now under way in our group (39) , as well as studies of various amounts of MAb2, their liposomal entrapment, and their anti-CT priming potential and/or memoryevoking capacity. The anti-caries anti-id immunization by Jackson et al. (11) was the first published attempt at anti-id vaccination by stimulation of the intestinal immune system, obviously a major concern since mucosae are the natural port of entry of most pathogens. However, in that study (11) , in which some protection was provided by the antistreptococcal anti-id vaccine, some ambiguity remained, because the challenge with the cariogenic streptococci, necessary to measure the protection, was done well before completion of the anti-id vaccine administrations, and this infection, therefore, could have induced some boosterlike effect in the anti-id vaccineprimed animals and/or could have primed the animals for subsequent anti-id vaccine responses. Another difference between the anti-id caries immunization (11) and our present data is the fact that both the rat antistreptococcal id Abs and the corresponding rabbit anti-id Abs were polyclonal and hence much more complex and less characterized, whereas both our id MAbl and anti-id MAb2 were well-defined MAbs. Furthermore, the presence of an internal image in the antistreptococcal anti-id Abs was deduced only from the fact that these injected Ab2's induced some protection, both by Since several authors agree that Ab2a and Ab2-y anti-id Abs can also immunize, without, however, providing details on protection (10, 38) , the question of whether the polyclonal anti-id Ab2s in that study (11) For protection against cholera disease, both Abs against CT and those against some vibrio cell wall antigen(s) are efficient and actually act synergistically in protection (33, 42) . This led to the use of the vaccine combining whole cells and CT-B that is presently being evaluated (2, 4, 5) . Although our anti-id MAb2 apparently protects against CT, it probably would not prevent vibrio colonization and multiplication. It might, therefore, be desirable to add another anti-id MAb, directed against some Ab, either polyclonal or monoclonal, against a cell wall antigen like, for example, the recently described Abs directed against the toxin-coregulated pilus of V. cholerae (41), a protein structure found on both major biotypes and serotypes of human pathogenic V. cholerae and thought mandatory for human and mouse gut colonization.
Intestinal (i.g. or ij.) immunizations against proteins, except CT, are usually not efficient in inducing high serum IgG and secretory IgA Ab titers (29) . However, it was recently reported (46) that the specialized epithelial M cells, which partly cover the Peyer's patches and are thought to be important for induction of many intestinal immune responses, have a special affinity for luminal Igs and antigen-Ab complexes, which are then actively transported from the external intestinal lumen into the internal mucosal milieu. This could be of obvious benefit for intestinal immunization with anti-id Abs, even more so if the affinity of M cells for Igs is independent of their isotype, as reported previously (46) . These new, attractive findings, together with our data and those of Jackson et al. (11) , suggest that intestinal anti-id immunization could become the subject of more studies in the nearby future, an obvious prerequisite for anti-id vaccination to eventually emerge from the speculative stage.
